Our Profile

Adcock Ingram is a leading South African pharmaceutical manufacturer, listed on the Johannesburg Stock Exchange.

The Company manufactures, markets and distributes a wide range of healthcare products. The company is a leading supplier to both the private and public sectors of the market.

Adcock Ingram is a level 4 B-BBEE contributor.

Expansion in to emerging markets has given the company a presence in sub-Saharan Africa and India.

Market leadership
Adcock Ingram is ranked as the second largest manufacturer in the private pharmaceutical market and is the second largest supplier to the public sector. Of note is the major share of the critical care market held by the company, being the largest supplier of critical care products to the public sector and hospitals. Adcock Ingram is a committed supplier of antiretroviral (ARV) medicines to the public sector through the highly competitive tender system.
Product ranges
Consumer and over-the-counter products constitute the largest segment of the Company's business in South Africa. Market-leading brands such as Panado have put the company in a leadership position in the private pharmacy market and the fast moving consumer goods (FMCG) segment.

The Prescription product range comprises medicines and technologies promoted to the healthcare professionals only. This portfolio includes a comprehensive range of generic medicines including antiretroviral medicines (ARVs). Partnerships with multinational pharmaceutical companies continue to augment the comprehensive portfolio of originator medicines.

The Critical Care portfolio offers a range of quality and affordable generic medicines with a flow of new molecules to continually expand the range. The Critical Care range has a long history in the Company based on an agreement with Baxter, and positions Adcock Ingram as the leading supplier of critical care products to the private and public sectors.
Local Manufacturing
Adcock Ingram has recently undertaken a capital expansion project costing R1.5 billion which was primarily focused on the regulatory compliance status of the three manufacturing facilities situated in Gauteng.

The High Volume Liquids facility situated at Clayville is a state of the art and highly automated factory primarily producing liquids and effervescent formulations.

The Tablet and Capsule facility situated at Wadeville is focused on the manufacture of antiretroviral medicines which are supplied to the public sector through the tender system.

The Critical Care facility situated at Aeroton produces intravenous fluids, blood bags, renal dialysis products and large and small-volume parenterals.
Distribution Investment
Adcock Ingram has invested in a state-of-the-art distribution system, designed to distribute the Company’s products as well as those of its contracted partners, direct to all customers.
International Expansion – Africa and India
Adcock Ingram operates in three hubs in sub-Saharan Africa, being West Africa (Ghana), East Africa (Kenya) and Southern Africa (Zimbabwe), marketing a wide range of ethical and consumer products. Manufacturing takes place in Ghana and Zimbabwe.

Adcock Ingram is invested in a manufacturing facility in Bangalore, India, which offers an alternative source of supply for the South African market.